BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 10908093)

  • 1. Mechanistic and clinical rationales for using beta-blockers in heart failure.
    Bristow MR
    J Card Fail; 2000 Jun; 6(2 Suppl 1):8-14. PubMed ID: 10908093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure.
    Khattar RS
    Minerva Cardioangiol; 2003 Apr; 51(2):143-54. PubMed ID: 12783070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN
    Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-Blocker therapy in heart failure.
    Doughty RN
    Heart Fail Monit; 2000; 1(1):2-7. PubMed ID: 12634875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of beta-blockers in patients with heart failure.
    Eichhorn EJ
    J Card Fail; 2000 Jun; 6(2 Suppl 1):40-6. PubMed ID: 10908097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.
    Udelson JE; Konstam MA
    J Card Fail; 2002 Dec; 8(6 Suppl):S465-71. PubMed ID: 12555159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Left ventricular diastolic heart failure with normal left ventricular systolic function in older persons.
    Aronow WS
    J Lab Clin Med; 2001 May; 137(5):316-23. PubMed ID: 11329528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease.
    Vonder Muhll I; Liu P; Webb G
    Int J Cardiol; 2004 Dec; 97 Suppl 1():25-33. PubMed ID: 15590076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From clinical trials to clinical practice: what we know and do not know about beta-blockers and the heart.
    Feldman AM
    J Card Fail; 2000 Jun; 6(2 Suppl 1):34-9. PubMed ID: 10908096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New therapeutic prospects in heart failure. ACE inhibitors and beta blockers].
    Capone A; Carfagna P; Paravati V; Bianco G; Battista M; Brandimarte C
    Recenti Prog Med; 1999 Mar; 90(3):136-42. PubMed ID: 10228352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of angiotensin converting enzyme inhibitors on remodeling in clinical trials.
    Greenberg BH
    J Card Fail; 2002 Dec; 8(6 Suppl):S486-90. PubMed ID: 12555162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study.
    Tsuyuki RT; Yusuf S; Rouleau JL; Maggioni AP; McKelvie RS; Wiecek EM; Wang Y; Pogue J; Teo KK; White M; Avezum A; Latini R; Held P; Lindgren E; Probstfield J
    Can J Cardiol; 1997 Dec; 13(12):1166-74. PubMed ID: 9444298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From left ventricular dysfunction to heart failure.
    Cleland JG
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11):1397-402. PubMed ID: 9092398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New concepts in post-infarction ventricular remodeling.
    Udelson JE; Patten RD; Konstam MA
    Rev Cardiovasc Med; 2003; 4 Suppl 3():S3-12. PubMed ID: 14564229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for left ventricular remodeling in heart failure.
    Frigerio M; Roubina E
    Am J Cardiol; 2005 Dec; 96(12A):10L-18L. PubMed ID: 16399088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z; Rogers JG
    Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Under-utilization of evidence-based drug treatment in patients with heart failure is only partially explained by dissimilarity to patients enrolled in landmark trials: a report from the Euro Heart Survey on Heart Failure.
    Lenzen MJ; Boersma E; Reimer WJ; Balk AH; Komajda M; Swedberg K; Follath F; Jimenez-Navarro M; Simoons ML; Cleland JG
    Eur Heart J; 2005 Dec; 26(24):2706-13. PubMed ID: 16183692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of heart failure based on large-scale clinical trials: renin-angiotensin system antagonists and beta-blockers].
    Kubota T; Takeshita A
    Nihon Rinsho; 2003 May; 61(5):801-6. PubMed ID: 12755006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.